Further, it would be of interest to study sCD163 and sPD-L1 in clinical settings, as additional prognostic tools in regard to follow-up schemes or as tools for monitoring patients with metastatic RCC undergoing targeted and/or immunotherapies. This evidence concerns the gene CD163 and renal cell carcinoma.